Fund+

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.